Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.73 |
| ▸ | DRD3 | P35462 | 11/20 | 0.98 |
| ▸ | DRD2 | P14416 | 10/20 | 0.98 |
| ▸ | DRD4 | P21917 | 7/20 | 0.65 |
| ▸ | DRD1 | P21728 | 5/20 | 0.65 |
| ▸ | DRD5 | P21918 | 5/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | PRCP | P42785 | 1/20 | 0.64 |
| ▸ | EBP | Q15125 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7023734 | 1.00 | DRD3 (0.98) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL873078 | 0.99 | DRD3 (1.00) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL873812 | 0.99 | DRD3 (1.00) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL873549 | 0.99 | DRD3 (1.00) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL29369425 | 0.99 | DRD3 (1.00) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| Hydrochloric Acid SCHEMBL5678691 | 0.98 | DRD3 (0.98) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| Hydrochloric Acid SCHEMBL5678697 | 0.98 | DRD3 (0.98) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| Hydrochloric Acid SCHEMBL29634866 | 0.98 | DRD3 (0.98) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL6880380 | 0.91 | DRD3 (0.84) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL6881711 | 0.91 | DRD3 (0.84) | DRD3DRD2SIGMAR1DRD4DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716854-B2 | 3-(3-(METHYLSULFONYL)PHENYL)-1-PROPYLPIPERIDINE; SUBSTITUTED PHENYLAZACYCLOALKANES; DOPAMINERGIC | PFIZER, INC. | 2004-04-06 | — | — | US | claimed |
| EP-1363634-A2 | COMPOUNDS FOR THE TREATMENT OF ADDICTIVE DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030212065-A1 | TREATMENTS FOR RESTLESS LEGS SYNDROME | MCBRINN SYLVIA (US) | 2003-11-13 | — | — | US | claimed |
| US-20030191149-A1 | Compounds for treating fibromyalgia and chronic fatigue syndrome | MCCALL ROBERT B (US) | 2003-10-09 | — | — | US | claimed |
| EP-1330248-A2 | NEW TREATMENTS FOR RESTLESS LEGS SYNDROME | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-30 | — | — | EP | claimed |
| US-20030078273-A1 | Compounds for the treatment of addictive disorders | ANDERSON RICHARD W (US) | 2003-04-24 | — | — | US | claimed |
| EP-1274430-A2 | COMPOUNDS FOR TREATING FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-15 | — | — | EP | claimed |
| US-20020143010-A1 | Compounds for treating fibromyalgia and chronic fatigue syndrome | MCCALL ROBERT B (US) | 2002-10-03 | — | — | US | claimed |
| US-20020107257-A1 | Treatments for restless legs syndrome | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| WO-2002036123-A2 | NEW TREATMENTS FOR RESTLESS LEGS SYNDROME | PHARMACIA & UPJOHN COMPANY (US) | 2002-05-10 | — | — | WO | claimed |
| US-20020049206-A1 | Compounds for the treatment of addictive disorders | PHARMACIA & UPJOHN (A DELAWARE CORPORATION) | 2002-04-25 | — | — | US | claimed |
| WO-2002013807-A2 | COMPOUNDS FOR THE TREATMENT OF ADDICTIVE DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-21 | — | — | WO | claimed |
| US-20020004510-A1 | Compounds for treating fibromyalgia and chronic fatigue syndrome | PHARMACIA & UPJOHN COMPANY | 2002-01-10 | — | — | US | claimed |
| WO-2001081343-A2 | COMPOUNDS FOR TREATING FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
| EP-1685838-A1 | Compounds for the treatment of addictive disorders | Pharmacia & Upjohn Company LLC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-6841557-B2 | Compounds for the treatment of addictive disorders | PHARMACIA & UPJOHN (US) | 2005-01-11 | — | — | US | disclosed |
| US-6716854-B2 | 3-(3-(METHYLSULFONYL)PHENYL)-1-PROPYLPIPERIDINE; SUBSTITUTED PHENYLAZACYCLOALKANES; DOPAMINERGIC | PFIZER, INC. | 2004-04-06 | — | — | US | disclosed |
| WO-2002013807-A2 | COMPOUNDS FOR THE TREATMENT OF ADDICTIVE DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| US-20020004510-A1 | Compounds for treating fibromyalgia and chronic fatigue syndrome | PHARMACIA & UPJOHN COMPANY | 2002-01-10 | — | — | US | disclosed |
| WO-2001081343-A2 | COMPOUNDS FOR TREATING FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049206-A1 | Compounds for the treatment of addictive disorders | OPRK1, SLC6A3, TACR2 | SIGMAR1 181/4885DRD3 26/4885DRD2 11/4885 |
| US-20020004510-A1 | Compounds for treating fibromyalgia and chronic fatigue syndrome | GRK5, GRK4, GPR35 | SIGMAR1 2565/4885DRD3 1356/4885DRD2 1359/4885 |
| US-20030078273-A1 | Compounds for the treatment of addictive disorders | OPRK1, SLC6A3, TACR2 | SIGMAR1 181/4885DRD3 26/4885DRD2 11/4885 |
| US-20020143010-A1 | Compounds for treating fibromyalgia and chronic fatigue syndrome | GRK5, GRK4, GPR35 | SIGMAR1 2565/4885DRD3 1356/4885DRD2 1359/4885 |
| US-20020107257-A1 | Treatments for restless legs syndrome | HCRTR2, PNMT, HCRTR1 | SIGMAR1 1403/4885DRD3 329/4885DRD2 189/4885 |
| US-20030212065-A1 | TREATMENTS FOR RESTLESS LEGS SYNDROME | HCRTR2, PNMT, HCRTR1 | SIGMAR1 1403/4885DRD3 329/4885DRD2 189/4885 |
| US-20030191149-A1 | Compounds for treating fibromyalgia and chronic fatigue syndrome | GRK5, GRK4, GPR35 | SIGMAR1 2565/4885DRD3 1356/4885DRD2 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.